JP2021528399A5 - - Google Patents

Info

Publication number
JP2021528399A5
JP2021528399A5 JP2020570143A JP2020570143A JP2021528399A5 JP 2021528399 A5 JP2021528399 A5 JP 2021528399A5 JP 2020570143 A JP2020570143 A JP 2020570143A JP 2020570143 A JP2020570143 A JP 2020570143A JP 2021528399 A5 JP2021528399 A5 JP 2021528399A5
Authority
JP
Japan
Prior art keywords
polypeptide
formulation
binds
formulation according
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/038600 external-priority patent/WO2019246595A1/en
Publication of JP2021528399A publication Critical patent/JP2021528399A/ja
Publication of JP2021528399A5 publication Critical patent/JP2021528399A5/ja
Pending legal-status Critical Current

Links

JP2020570143A 2018-06-22 2019-06-21 胆道癌を治療する際に使用するための標的TGF−β阻害のための投薬計画 Pending JP2021528399A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862688476P 2018-06-22 2018-06-22
US62/688,476 2018-06-22
US201962855205P 2019-05-31 2019-05-31
US62/855,205 2019-05-31
PCT/US2019/038600 WO2019246595A1 (en) 2018-06-22 2019-06-21 Dosing regimens for targeted tgf-b inhibition for use in treating biliary tract cancer

Publications (2)

Publication Number Publication Date
JP2021528399A JP2021528399A (ja) 2021-10-21
JP2021528399A5 true JP2021528399A5 (cg-RX-API-DMAC7.html) 2022-09-12

Family

ID=68982740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570143A Pending JP2021528399A (ja) 2018-06-22 2019-06-21 胆道癌を治療する際に使用するための標的TGF−β阻害のための投薬計画

Country Status (14)

Country Link
US (1) US20210214446A1 (cg-RX-API-DMAC7.html)
EP (1) EP3810654A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021528399A (cg-RX-API-DMAC7.html)
KR (1) KR20210022680A (cg-RX-API-DMAC7.html)
CN (1) CN112673020A (cg-RX-API-DMAC7.html)
AU (1) AU2019288765A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020026159A2 (cg-RX-API-DMAC7.html)
CA (1) CA3103908A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003323A1 (cg-RX-API-DMAC7.html)
IL (1) IL279647A (cg-RX-API-DMAC7.html)
MX (1) MX2020014166A (cg-RX-API-DMAC7.html)
SG (1) SG11202012688UA (cg-RX-API-DMAC7.html)
TW (1) TW202019959A (cg-RX-API-DMAC7.html)
WO (1) WO2019246595A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304979A (zh) * 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2023045141A1 (zh) * 2021-09-26 2023-03-30 上海迈泰君奥生物技术有限公司 一种双功能融合蛋白

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210977T1 (hr) * 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US10906957B2 (en) * 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
CN110198738A (zh) * 2017-01-07 2019-09-03 默克专利有限公司 用于靶向的TGF-β抑制的给药方案和剂型

Similar Documents

Publication Publication Date Title
CN106604750B (zh) 治疗骨髓瘤
JP2019517549A5 (cg-RX-API-DMAC7.html)
JP2016530280A5 (cg-RX-API-DMAC7.html)
TW201922793A (zh) Pd-1抗體和vegfr抑制劑聯合治療小細胞肺癌的用途
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
JP2012067116A5 (cg-RX-API-DMAC7.html)
WO2013152034A1 (en) Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
JP2020510039A5 (cg-RX-API-DMAC7.html)
JP2015517529A5 (cg-RX-API-DMAC7.html)
JP2015500822A5 (cg-RX-API-DMAC7.html)
JP2015525798A5 (cg-RX-API-DMAC7.html)
TW201922282A (zh) Pd-1抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途
JP2021527083A5 (cg-RX-API-DMAC7.html)
JP2019521156A5 (cg-RX-API-DMAC7.html)
TW202330040A (zh) 抗her2抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2018512402A5 (cg-RX-API-DMAC7.html)
CN101657215A (zh) 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物
JP2020517671A5 (cg-RX-API-DMAC7.html)
JP2021523096A5 (cg-RX-API-DMAC7.html)
JP2009544610A5 (cg-RX-API-DMAC7.html)
JP2021529777A5 (cg-RX-API-DMAC7.html)
CN111166878B (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
WO2020236668A1 (en) Leukadherin-1 alone or in combination for use in the treatment of cancer
JP2009538916A5 (cg-RX-API-DMAC7.html)
JP2024521105A5 (cg-RX-API-DMAC7.html)